Clinical Trials Browser

Interventional × Polycythemia × GRN163L peptide × Clear all

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Phase 3 Active not recruiting

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis